Abstracts tagged "Scleroderma, Systemic"

Abstract Number: 1563 • ACR Convergence 2025
RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis
Dinesh Khanna¹, Monalisa Ghosh¹, Ankoor Shah², Sonali Bracken³, george georges⁴, Carrie Richardson⁵, Pei-Suen Tsou¹, Charles Ross⁶, Carleigh Zahn¹, Courtney Little⁷, Carl diCasoli⁷, Mikaela Raymond⁷, Adreeja GuhaRay⁷, Jenell Volkov⁷, Daniel Nunez⁷, Thomas Furmanak⁷, Jason Stadanlick⁷, Larissa Ishikawa⁷, Zachary Vorndran⁷, Alexandra Ellis⁷, Jazmean Williams⁷, Steve Flanagan⁷, Quynh Lam⁸, Domenick Braccia⁸, Fatemeh Hadi-Nezhad⁸, Raj Tummala⁸, Samik Basu⁷ and David Chang⁹, ¹University of Michigan, Ann Arbor, MI, ²Duke University, Durham, NC, ³Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁴Northwestern Medicine, Evanston, IL, ⁵Northwestern University, Chicago, IL, ⁶University of Michigan, Ann Arbor, ⁷Cabaletta Bio, Philadelphia, PA, ⁸Cabaletta Bio, Philadelphia, ⁹Cabaletta Bio, Bryn Mawr, PA
Background/Purpose: The treatment goals for systemic sclerosis (SSc) are to control disease activity, limit progression of organ damage and decrease long-term morbidity and mortality. Therapies…
Abstract Number: 0685 • ACR Convergence 2025
Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention
Areeka Memon¹, Monique Hinchcliff² and Amir Masoud³, ¹Yale New Haven Health, New Haven, CT, ²Yale School of Medicine, Westport, CT, ³Hartford Healthcare, hartford
Background/Purpose: Gastrointestinal tract (GIT) symptoms impact up to 90% of individuals with SSc. Hiatal hernia, decreased esophageal contractility, and lower esophageal sphincter tone contribute to…
Abstract Number: 2476 • ACR Convergence 2025
Blinatumomab in rapid progressive systemic sclerosis
Christina Gebhardt¹, Franziska Szelinski², Hector Rincon-Arevalo², Giulia Magno³, Veit Buecklein³, Gerulf Haenel⁴, Gerhard Zugmaier⁵, Michael von Bergwelt³, Marion Subklewe³, Thomas Dörner⁶, Alla Skapenko⁷ and Hendrik Schulze-Koops⁷, ¹LMU Hospital, Division for Rheumatology and Clinical Immunology, München, Germany, ²Charite Universitétsmedizin Berlin, Germany, Berlin, Germany, ³LMU Klinikum, Med. Klinik und Poliklinik III, Munich, Germany, ⁴LMU Gene Center, Munich, Germany, ⁵Amgen, Munich, Germany, ⁶Charite Universitétsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ⁷LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany
Background/Purpose: Systemic sclerosis is a severe, potentially fatal disease, characterized by progressive fibrosis of skin and internal organs. Blinatumomab is a bispecific CD3/CD19-T-cell engager (BiTe)…
Abstract Number: 1562 • ACR Convergence 2025
Vasodilation with Prostanoids Influences Progression of Systemic Sclerosis-Associated Interstitial Lung Disease: a EUSTAR Cohort Study
adela cristina sarbu¹, Liubov Petelytska², lorenzo tofani³, Gianluca Moroncini⁴, Alexandra Balbir-Gurman⁵, elisabetta zanatta⁶, Jörg Henes⁷, paolo airò⁸, Marco Matucci-Cerinic⁹, Ana Maria Gheorghiu¹⁰, antonella marcoccia¹¹, branimir Anić¹², Jelena Colic¹³, Daniel Furst¹⁴, julia Spierings¹⁵, Francesco Del Galdo¹⁶, Britta Maurer¹⁷, Anna-Maria Hoffmann-Vold¹⁸, Oliver Distler¹⁹ and Cosimo Bruni²⁰, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. • Department of Rheumatology and Immunology, Bern University Hospital, University of Bern, Bern, Switzerland, bern, Swaziland, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. • Dept Internal Medicine #³, Bogomolets National Medical University, Kyiv, Ukraine, Kyiv, Ukraine, ³Department of Statistics, Informatics and Applications, University of Florence, Florence, Italy, firenze, Italy, ⁴Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, ⁵• Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Tecchnion, Haifa, Israel, Haifa, Israel, ⁶Padova University Hospital, Rheumatology Unit, Padova, Italy, padova, Italy, ⁷Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ⁸Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, brescia, Italy, ⁹University San Raffaele Milano, Milano, Milan, Italy, ¹⁰Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ¹¹Centro di Riferimento Interdisciplinare per la Sclerosi Sistemica (CRIIS), Roma, Italy, rome, Italy, ¹²Department of Internal Medicine, Division of Clinical Immunology and Rheumatology, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Croatia, zagreb, Croatia, ¹³Institute of Rheumatology Belgrade, Belgrade, Serbia, Belgrade, Serbia, ¹⁴Southern California Scleroderma and Rheumatology Center, Los Angeles, CA, ¹⁵Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, ¹⁶University of Leeds, Leeds, United Kingdom, ¹⁷Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ¹⁸Oslo University Hospital, Oslo, Norway, ¹⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ²⁰University of Zurich, Zurich, Switzerland
Background/Purpose: Although most vasoactive vasodilating drugs (VVDs) exert anti-fibrotic effects in pre-clinical studies, randomized controlled trials assessing their efficacy in systemic sclerosis-associated interstitial lung disease…
Abstract Number: 0683 • ACR Convergence 2025
Symptom-Based Clustering of Gastrointestinal Involvement in Systemic Sclerosis
Ali Ayla¹, Ernesto Calderon Martinez², Meng Zhang³, Claudia Pedroza⁴, Bingrui Chen⁵, Ashish Balar⁵, Michael Hughes⁶, Silvia Bellando Randone⁷, Brian Skaug¹, Maureen Mayes⁸, Shervin Assassi⁹ and Zsuzsanna McMahan¹⁰, ¹UTHealth Houston Division of Rheumatology, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Division of Rheumatology, Houston, ⁴UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ⁵UTHealth Houston, Houston, TX, ⁶Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁷University of Florence, Florence, Italy, ⁸UT Health Houston Division of Rheumatology, Houston, TX, ⁹Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ¹⁰UT Health Houston, Houston, TX
Background/Purpose: Virtually all patients with systemic sclerosis (SSc) experience gastrointestinal (GI) manifestations over the course of their disease, affecting any region from the mouth to…
Abstract Number: 2472 • ACR Convergence 2025
Digesting the data: tracking gastro-intestinal manifestations in systemic sclerosis over time
Cosimo Bruni¹, Jasmin Klöti², Aurora Maria Tatu³, Lea Stamm², Rucsandra Dobrota⁴, Muriel Elhai⁵, Mike Becker⁶, Sinziana Muraru⁷, Gesa Sauer⁸, Anna-Maria Hoffmann-Vold⁹, Oliver Distler¹⁰ and Carina Mihai¹¹, ¹University of Zurich, Zurich, Switzerland, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Department of Gastroenterology, University Hospital Zurich, University of Zurich, ⁸⁰⁹¹, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁵University Hospital zurich, Zürich, Switzerland, ⁶Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁷University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, zurich, Switzerland, ⁹Oslo University Hospital, Oslo, Norway, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹¹University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Gastrointestinal (GI) involvement is among the most frequent organ manifestations in systemic sclerosis (SSc), yet the timing of presentation of GI manifestations remains incompletely…
Abstract Number: 1561 • ACR Convergence 2025
Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion
Carlos de la Puente-Bujidos¹, Antia Garcia Fernandez², Verónica García García¹, Jesús Loarce³ and Sandra Garrote-Corral¹, ¹Ramón y Cajal University Hospital, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Ramón y Cajal University Hospital, Madrid, Spain
Background/Purpose: In 2019 a European expert consensus suggested that all patients with systemic sclerosis (SSc) should be screened with HRCT for interstitial lung disease (ILD)…
Abstract Number: 0674 • ACR Convergence 2025
Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis
Ian Odell¹, Crystal Cheung¹, Megan Wu², Stephanie Perez³, Agrani Dixit⁴, Cassandra van Horn³, Muhammad Hamdan⁵, Baran Gunes⁶, Sophia Kujawski⁷, Hyojeong Lee³, Annie Wang³, Denise Esserman⁸, Michael Zamani⁹, F. Perry Wilson³, John Onofrey³, Xenophon Papademetris³ and Monique Hinchcliff¹⁰, ¹Yale University School of Medicine, New Haven, CT, ²Yale University School of Medicine, Greenville, ³Yale University School of Medicine, New Haven, ⁴Yale School of Medicine, New Haven, CT, ⁵Yale University School of Medicine, Mansfield, ⁶Yale University School of Medicine, Pompton Plains, NJ, ⁷The George Washington University, New Haven, CT, ⁸Yale University School of Public Health, New Haven, ⁹Independent Statistician, Washington D.C., ¹⁰Yale School of Medicine, Westport, CT
Background/Purpose: Calcinosis cutis (CC) is a disabling skin condition associated with systemic sclerosis (SSc). Although many CC treatments including sodium thiosulfate (STS) have been proposed,…
Abstract Number: 1865 • ACR Convergence 2025
Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multi-omics analysis
Hanlin Yin¹, Wanyi Lin², Zhangyi zhao¹, Chenhan Jia¹ and Liangjing Lu¹, ¹Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China (People's Republic), ²Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China (People's Republic)
Background/Purpose: Antinuclear antibodies (ANA) are detected in over 95% of systemic sclerosis (SSc) patients. Compared to cutaneous subtype classification, autoantibody-based stratification more accurately predicts survival,…
Abstract Number: 1557 • ACR Convergence 2025
Association between Thoracic Muscle and Fat Area and Density and Pulmonary Function in Systemic Sclerosis
Aradhna Agarwal¹, Niki Pradhan¹, James St. Clair², Dinesh Khanna³ and Elana Bernstein⁴, ¹Columbia University Medical Center, New York, NY, ²University of Michigan, Ann Arbor, ³University of Michigan, Ann Arbor, MI, ⁴Columbia University, New York, NY
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis (SSc). Little is known about the association between body composition and…
Abstract Number: 0880 • ACR Convergence 2025
Detecting Interstitial Lung Disease and Identifying Extensive Disease on Chest Computed Tomography in Patients with Systemic Sclerosis: Cut-Offs for Lung Texture Analysis and its Prognostic Implications
Nicholas landini¹, lisa Jungblut², cecilia strappa³, Christian Blüthgen², Rucsandra Dobrota⁴, Muriel Elhai⁵, Carina Mihai⁶, Sinziana Muraru-Carbune², Martina Orlandi⁷, mariaelena Occhipinti⁸, Khadija El-Aoufy⁹, Gemma Lepri¹⁰, valeria panebianco¹¹, anna rita larici³, Anna-Maria Hoffmann-Vold¹², Cosimo Nardi¹³, Serena Guiducci¹⁴, Silvia Bellando-Randone¹⁵, Marco Matucci-Cerinic¹⁶, Thomas Frauenfelder², Oliver Distler¹⁷ and Cosimo Bruni¹⁸, ¹Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ²Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ³Advanced Radiology Center, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy, rome, Italy, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁵Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland, ⁶University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., modena, Italy, ⁸Division of Radiology, Fondazione Toscana Gabriele Monasterio, Pisa, Italy., pisa, Italy, ⁹Department of Health Science, University of Florence, Florence, Italy., firenze, Italy, ¹⁰Department of Experimental and Clinical Medicine, University of Florence, Division of Rheumatology Scleroderma Unit, AOU Careggi Hospital, Florence, Italy., Florence, Italy, ¹¹Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy., Rome, Italy, ¹²Oslo University Hospital, Oslo, Norway, ¹³Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. ², University of Florence - Azienda Ospedaliero-Universitaria Careggi, Florence, Italy, Florence, Italy, ¹⁴Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, ¹⁵University of Florence, Florence, Florence, Italy, ¹⁶University San Raffaele Milano, Milano, Milan, Italy, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹⁸University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with systemic sclerosis (SSc), especially in case of extensive disease detected on…
Abstract Number: 1862 • ACR Convergence 2025
Comprehensive analysis of the major histocompatibility complex in systemic sclerosis-associated interstitial lung disease identifies novel associated loci and potential progression biomarkers
Carlos de la Rosa Báez¹, Carlos Rangel Peláez¹, Inmaculada Rodríguez Martín¹, Martin Kerick¹, Alfredo guillen-del-castillo², Carmen Pilar Simeon³, Jose Luis Callejas⁴, Alexandre Voskuijl⁵, Alexander Kreuter⁶, Oliver Distler⁷, Susanna Proudman⁸, Mandana Nikpour⁹, Nicolas Hunzelmann¹⁰, Jeska de Vries-Bouwstra¹¹, Ariane Herrick¹², Yannick Allanore¹³, Lorenzo Beretta¹⁴, Maureen Mayes¹⁵, Christopher Denton¹⁶, Shervin Assassi¹⁷, Javier Martin¹ and Marialbert Acosta-Herrera¹, ¹Department of Cell Biology and Immunology, Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain, ²Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d’Hebron, Barcelona, Spain, ³Department of Internal Medicine, Hospital Universitario Vall d’Hebron, Barcelona, Spain, ⁴Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ⁶Department of Dermatology, Venereology, and Allergology, Helios St. Elisabeth Klinik Oberhausen, University Witten-Herdecke, Oberhausen, Germany, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ⁸Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁹University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia, ¹⁰Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany, ¹¹Leiden University Medical Center, Leiden, Netherlands, ¹²The University of Manchester, UK, Aberdeen, United Kingdom, ¹³Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France, ¹⁴Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹⁵UT Health Houston Division of Rheumatology, Houston, TX, ¹⁶University College London, UK, London, United Kingdom, ¹⁷Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX
Background/Purpose: The main causes of death in systemic sclerosis (SSc) are pulmonary complications such as SSc-associated interstitial lung disease (SSc-ILD). SSc-ILD is highly heterogeneous and…
Abstract Number: 1398 • ACR Convergence 2025
Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health
R. Mohamad Javier¹, Bernadus Bramantyo², Arkan Berlian³, Mahardika Nugraha⁴, Azzura Simanulang¹, Eko Setyo Herwanto⁵, Athaya Febriantyo Purnomo⁶, Jonathan Jonathan⁷, Ananingati Ananingati⁵, Budi Prakoso⁸ and Aisyah Rizki Nirmala Hanum⁵, ¹University of Indonesia Hospital, Jakarta Selatan, Jakarta Raya, Indonesia, ²Sardjito General Hospital, Daerah Istimewa Yogyakarta, Yogyakarta, Indonesia, ³Dr. Cipto Mangunkusumo Hospital, Jakarta Barat, Jakarta Raya, Indonesia, ⁴Universitas Islam Sultan Agung, KOTA SEMARANG, Jawa Tengah, Indonesia, ⁵Universitas Muhammadiyah Malang, Malang, Jawa Timur, Indonesia, ⁶Saiful Anwar General Hospita, Malang, Jawa Timur, Indonesia, ⁷RSUD Kalideres, Jakarta, Jakarta Raya, Indonesia, ⁸Department of Internal Medicine, RST dr Soepraoen, Malang, Jawa Timur, Indonesia
Background/Purpose: Autoimmune rheumatic diseases such as Sjögren’s Syndrome (SS) and Systemic Sclerosis (SSc) can significantly impact reproductive health and increase maternal cardiovascular risk. These conditions…
Abstract Number: 0879 • ACR Convergence 2025
Trajectories and risk factors of interstitial lung disease in limited cutaneous systemic sclerosis from the EUSTAR cohort
Antonio Tonutti¹, Francesca Motta¹, Silvia Bellando Randone², Nicoletta Del Papa³, Elisabetta Zanatta⁴, Marie-Elise Truchetet⁵, Christina Bergmann⁶, Gábor Kumánovics⁷, Monique Hinchcliff⁸, Yasser El Miedany⁹, Britta Maurer¹⁰, Marie Vanthuyne¹¹, Lijun Zhang¹², Nune Manukyan¹³, Carlo Selmi¹⁴ and Maria De Santis¹, ¹Humanitas University, Pieve Emanuele, Italy, ²University of Florence, Florence, Italy, ³ASST Pini CTO, Milano, Milan, Italy, ⁴University of Padua, Padova, Italy, ⁵University of Bordeaux, Bordeaux, France, ⁶Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁷University of Pecs, Pecs, Hungary, ⁸Yale School of Medicine, Westport, CT, ⁹Egyptian Society for Microcirculation in Rheumatic Diseases, Cairo, Egypt, ¹⁰Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ¹¹Université Catholique de Louvain, Bruxelles, Belgium, ¹²The University of Hong Kong-Shenzhen Hospital, Shenzhen, China (People's Republic), ¹³Mikaelyan Institute Of Surgery, Yerevan, Armenia, ¹⁴Humanitas University, Milan, Italy
Background/Purpose: Interstitial lung disease (ILD) is traditionally associated with the diffuse subset of systemic sclerosis (dcSSc) but may be observed in limited SSc (lcSSc), with…
Abstract Number: 1860 • ACR Convergence 2025
GLUT and FAPα as molecular imaging markers for interstitial lung disease in systemic sclerosis
Bo Broens¹, Conny van der Laken¹, Teodora Radonic¹, Douwe Mulder², esther Nossent¹, Yehya Al-Adwi², Tji Gan², Wim Timens², Alexandre Voskuijl³ and Jan Willem Duitman¹, ¹Amsterdam UMC, Amsterdam, Netherlands, ²UMCG Groningen, Groningen, Netherlands, ³Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: The clinical management of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is challenging due to its heterogeneous progression. While recent studies have shown that pulmonary…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].